Creative Biolabs' Custom Polyplex Development Service creates optimized polyplex nanocarriers (anionic mRNA and cationic polymers) for gene therapy, genetic vaccines, and protein replacement, protecting mRNA from nucleases and aiding cellular internalization.
It leverages polymer chemistry and proprietary nano micelle techniques, offers customizable components, ensures high stability, minimal immunogenicity, superior transfection efficiency, and facilitates endosomal escape to maximize protein expression, de-risking delivery, and accelerating pre-clinical success.
Discover How We Can Help - Request a ConsultationThe core mechanism involves the spontaneous electrostatic interaction between the polycationic polymer (e.g., modified PEI, PEG-PAsp(DET)) and the negatively charged phosphate backbone of the mRNA. This interaction creates the polyplex nanoparticle. Our advanced PNMs are designed with PEGylated components that form a stabilizing micelle structure. Crucially, the internal cationic polymer is engineered to enable the "proton sponge effect" upon endosomal uptake, leading to endosome rupture and the immediate release of the mRNA into the cytosol, where protein translation can occur.
Fig.1 Preparation of polymer nanomicelles loaded with mRNA and measurement of their physicochemical properties by DLS.1
The high efficacy and tunability of custom polyplexes make them ideally suited for diverse therapeutic applications:
Our Custom Polyplex Development Service offers distinct advantages:
Our structured, phased workflow is designed for clarity, efficiency, and seamless integration with your drug development schedule, suitable for visualization as a comprehensive flowchart.
Required starting materials include target mRNA sequence (or construct details), target cell type/organ (e.g., T-cells, joint chondrocytes), and desired administration route; conduct in-depth consultation to define N/P ratio, polymer molecular weight, and architecture (linear vs. branched) based on the required therapeutic dose.
Required materials are customized cationic block copolymers (e.g., PEG-PAsp(DET) variants) and targeting ligands; perform batch-to-batch polymer synthesis with quality control to ensure a narrow polydispersity index (PDI ≈ 0.12-0.16) and consistent chemical substitution ratio.
Optimize self-assembly and conduct sterile filtration; systematically adjust charge ratios and mixing conditions to achieve optimal particle size (≤ 200 nm) and zeta potential (near-neutral for "stealth" carriers).
Carry out comprehensive structural and stability analysis, including Dynamic Light Scattering (DLS), Zeta Potential measurement, Cryo-TEM imaging, and RNase stability assays.
Activities: Conduct in vitro and in vivo transfection and toxicity studies; use reporter mRNA (e.g., Luciferase) to quantify transfection rates, duration of expression (verified ≥ 6 days), and endosomal escape kinetics (confirmed < 20 min release).
The typical timeframe for this custom service ranges from 10 to 18 weeks, depending on the complexity of the polymer required and the scope of the in vivo validation requested.
As an expert seller, Creative Biolabs provides a high-performance, one-stop delivery solution that eliminates the typical bottlenecks in mRNA development. Our expertise is focused on engineering Polyplex Nanomicelles that achieve unparalleled stability and transfection success.
Customized Polymer Engineering & Synthesis
Tailored to your unique mRNA payload, leveraging proprietary chemistries to ensure maximum stability and biocompatibility.
Proprietary Block Copolymers
Optimized systems (e.g., PEG-PAsp(DET)) enable robust, rapid endosomal escape and cytosolic release (under 20 minutes), proven to boost transfection rates.
Precision Physicochemical Control
Guarantees uniform particle size (≤ 200 nm) and near-neutral "stealth" zeta potential, reducing toxicity and extending systemic circulation.
Expert Ligand Functionalization
Enables highly selective, receptor-mediated cell targeting for tissue-specific delivery, minimizing off-target effects.
Rigorous In Vivo & In Vitro Validation
Confirms up to sevenfold increased transfection efficiency and sustained gene expression (≥ 6 days) compared to unformulated mRNA.
Structured Quality-by-Design (QbD) Workflow
Culminates in a scalable, fully documented manufacturing protocol, ready for cGMP transition.
One-Stop Full-Cycle Service
Covers custom polymer design, synthesis, and functional in vivo proof-of-concept studies—all provided by Creative Biolabs.
Self-assembled nanomicelles were prepared by labeling Luc2 mRNA with fluorescein and mixing it with PEG-PAsp (DET), which was used to study the endocytosis of mRNA nanomicelles and the rapid release of mRNA drug loads. Data show that the green mRNA drug fuses with the red early endosome and is rapidly released and evenly diffused into the cytoplasm within less than 20 minutes after the administration of the mRNA drug.
Fig.2 The green mRNA drug fuses with the red early endosome and is rapidly released and evenly diffused into the cytoplasm within less than 20 minutes after administration.1
A: LNPs are excellent, but polyplexes often demonstrate superior structural stability in serum due to the strong electrostatic binding between the polymer and mRNA. Our advanced PNMs, with their near-neutral zeta potential and precise size control, are specifically engineered to offer a strong safety profile with low immunogenicity, making them a highly competitive and customizable non-viral alternative.
A: Absolutely. Our core capability is the functionalization of the polymer backbone with targeting ligands (peptides, antibodies). This enables receptor-mediated cell uptake, which is critical for maximizing delivery to specific cell types (e.g., immune cells or tumor cells) and minimizing off-target effects. We welcome collaboration on your specific targeting strategy.
A: The most significant challenge is endosomal escape. Our PNM platform is proven to facilitate the rapid release of mRNA into the cytosol in under 20 minutes after cellular uptake. This capability, validated through advanced imaging techniques, is the reason our formulations achieve up to sevenfold higher transfection efficiency than naked mRNA.
A: Yes. The chemical synthesis of our block copolymers is highly reproducible, and the polyplex formation is based on spontaneous electrostatic self-assembly—a simple, scalable process. We ensure our final protocol is robust, consistent in size and PDI, and ready for seamless technology transfer to large-scale cGMP manufacturing.
The future of therapeutics relies on sophisticated delivery. Creative Biolabs' Custom Polyplex Development Service provides the essential stability, targeting, and efficacy needed to translate your mRNA research into a successful therapeutic reality. We offer end-to-end expertise, from custom polymer synthesis and rigorous characterization to functional in vivo validation.
Contact Our Team for More Information and to Discuss Your Project| Cat. No | Product Name | Promoter |
|---|---|---|
| CAT#: GTVCR-WQ001MR | IVTScrip™ pT7-mRNA-EGFP Vector | T7 |
| CAT#: GTVCR-WQ002MR | IVTScrip™ pT7-VEE-mRNA-EGFP Vector | T7 |
| CAT#: GTVCR-WQ003MR | IVTScrip™ pT7-VEE-mRNA-FLuc Vector | T7 |
| CAT#: GTVCR-WQ87MR | IVTScrip™ pT7-VEE-mRNA-Anti-SELP, 42-89-glycoprotein Vector | T7 |
| Cat. No | Product Name | Type |
|---|---|---|
| CAT#: GTTS-WQ001MR) | IVTScrip™ mRNA-EGFP (Cap 1, 30 nt-poly(A)) | Reporter Gene |
| CAT#: GTTS-WK18036MR | IVTScrip™ mRNA-Human AIMP2, (Cap 1, Pseudo-UTP, 120 nt-poly(A)) | Enzyme mRNA |
| (CAT#: GTTS-WQ004MR) | IVTScrip™ mRNA-Fluc (Cap 1, 30 nt-poly(A)) | Reporter Gene |
| (CAT#: GTTS-WQ009MR) | IVTScrip™ mRNA-β gal (Cap 1, 30 nt-poly(A)) | Reporter Gene |
Reference
